These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 24336067

  • 1. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
    Pishas KI, Neuhaus SJ, Clayer MT, Schreiber AW, Lawrence DM, Perugini M, Whitfield RJ, Farshid G, Manavis J, Chryssidis S, Mayo BJ, Haycox RC, Ho K, Brown MP, D'Andrea RJ, Evdokiou A, Thomas DM, Desai J, Callen DF, Neilsen PM.
    Cancer Res; 2014 Feb 01; 74(3):921-31. PubMed ID: 24336067
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.
    Oncogene; 2007 May 24; 26(24):3473-81. PubMed ID: 17146434
    [Abstract] [Full Text] [Related]

  • 8. Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin.
    Laroche A, Tran-Cong K, Chaire V, Lagarde P, Hostein I, Coindre JM, Chibon F, Neuville A, Lesluyes T, Lucchesi C, Italiano A.
    PLoS One; 2015 May 24; 10(10):e0137794. PubMed ID: 26427052
    [Abstract] [Full Text] [Related]

  • 9. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
    Crane EK, Kwan SY, Izaguirre DI, Tsang YT, Mullany LK, Zu Z, Richards JS, Gershenson DM, Wong KK.
    PLoS One; 2015 May 24; 10(8):e0135101. PubMed ID: 26248031
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.
    J Natl Cancer Inst; 2009 Nov 18; 101(22):1562-74. PubMed ID: 19903807
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ.
    Clin Cancer Res; 2007 Jun 01; 13(11):3380-7. PubMed ID: 17545546
    [Abstract] [Full Text] [Related]

  • 12. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
    Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Bueno-Silva B, de Alencar SM, Lombardi P, Mao W, Montalto G, Cervello M, Rakus D, Gizak A, Lin HL, Libra M, Akula SM, McCubrey JA.
    Adv Biol Regul; 2019 May 01; 72():22-40. PubMed ID: 30898612
    [Abstract] [Full Text] [Related]

  • 13. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M.
    Blood; 2006 Aug 01; 108(3):993-1000. PubMed ID: 16543464
    [Abstract] [Full Text] [Related]

  • 14. RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas.
    Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J.
    Cancer Invest; 2015 Aug 01; 33(9):440-50. PubMed ID: 26288114
    [Abstract] [Full Text] [Related]

  • 15. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT.
    Proc Natl Acad Sci U S A; 2006 Feb 07; 103(6):1888-93. PubMed ID: 16443686
    [Abstract] [Full Text] [Related]

  • 16. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S, Yamato K, Hirai S, Moriwaki T, Fukuda K, Suzuki H, Abei M, Nakagawa I, Hyodo I.
    Cancer Sci; 2011 Mar 07; 102(3):605-13. PubMed ID: 21205074
    [Abstract] [Full Text] [Related]

  • 17. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ, Vega F, Medeiros LJ.
    Leukemia; 2011 May 07; 25(5):856-67. PubMed ID: 21394100
    [Abstract] [Full Text] [Related]

  • 18. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
    Palani CD, Beck JF, Sonnemann J.
    Invest New Drugs; 2012 Feb 07; 30(1):25-36. PubMed ID: 20680659
    [Abstract] [Full Text] [Related]

  • 19. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.
    Duan L, Perez RE, Chen L, Blatter LA, Maki CG.
    J Mol Cell Biol; 2018 Aug 01; 10(4):331-340. PubMed ID: 29190376
    [Abstract] [Full Text] [Related]

  • 20. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
    Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, Castaño E, Acebes JJ, Giménez-Bonafé P, Gil J, Tortosa A.
    PLoS One; 2011 Apr 05; 6(4):e18588. PubMed ID: 21483692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.